BR3005
/ Boryung Group
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 24, 2024
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
May 24, 2024
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=47 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 04, 2024
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 04, 2024
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=46 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 4
Of
4
Go to page
1